Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | NQO1 | P15559 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107208 | 0.94 | ADORA3 (0.53) | ADORA3NQO1MEN1KMT2APOLB | |
| SCHEMBL4959579 | 0.91 | ADORA3 (0.60) | ADORA3NQO1MEN1KMT2APOLB | |
| SCHEMBL7219960 | 0.87 | NQO1 (0.44) | ADORA3NQO1MEN1KMT2ACYP2C9 | |
| SCHEMBL7219958 | 0.86 | NQO1 (0.42) | ADORA3NQO1CYP2C9 | |
| SCHEMBL4960324 | 0.86 | NQO1 (0.57) | ADORA3NQO1MEN1KMT2ACYP2C9 | |
| SCHEMBL4961559 | 0.85 | NQO1 (0.53) | ADORA3NQO1CYP2C9CRHBPCASP7 | |
| SCHEMBL4962451 | 0.83 | NQO1 (0.52) | ADORA3NQO1CYP2C9 | |
| SCHEMBL6924340 | 0.82 | NQO1 (0.53) | ADORA3NQO1MEN1KMT2ACYP2C9 | |
| SCHEMBL6918020 | 0.82 | NQO1 (0.50) | ADORA3NQO1CYP2C9 | |
| SCHEMBL1649145 | 0.81 | ADORA3 (0.65) | ADORA3NQO1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | claimed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | claimed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| EP-1383756-B1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | ARYX THERAPEUTICS (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7145020-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2006-12-05 | — | — | US | disclosed |
| US-6864279-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | ESPERO BIOPHARMA, INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1383756-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | Arxy Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2002085882-A1 | COUMARIN DERIVATIVES TO BE USED AS ANTICOAGULANTS | ARXY THERAPEUTICS (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199573-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885NQO1 249/4885MEN1 1924/4885 |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885NQO1 249/4885MEN1 1924/4885 |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885NQO1 249/4885MEN1 1924/4885 |
| US-20040220258-A1 | Materials and methods for treating coagulation disorders | CES1, F2, CYP3A5 | ADORA3 2300/4885NQO1 249/4885MEN1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.